Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter StudyJingran Ji, Jonathan W. Riess, Andrew J. Piper‐Vallillo et al.|JTO Clinical and Research Reports|2023Cited by 39